Mounjaro and High Blood Pressure: A UK Guide
Published on: April 19, 2026
If you've been prescribed Mounjaro — or you're thinking about starting it — and you already take tablets for high blood pressure, you've probably asked yourself the same question a lot of our patients do. Is this safe? Will it push my numbers the wrong way, or make me feel faint?
It's a fair worry. Hypertension is common in the UK: roughly one in three adults has it, and most people starting a weight loss medication aren't beginning from a clean bill of health. The good news is that the current evidence is, on balance, reassuring. For most people with well-controlled high blood pressure, Mounjaro (tirzepatide) isn't only safe — it can actually help bring your readings down. But there are a few situations where your GP or pharmacist needs to be involved before you start, and some practical monitoring steps that will make the first few months smoother.
This guide pulls together what the clinical trials show, what the MHRA advises in the UK, and what we'd want you to know if you were sitting across from one of our pharmacists. Written for anyone starting Mounjaro with a history of high blood pressure, or who develops concerns about their BP while on treatment.
How Mounjaro affects blood pressure
Mounjaro is the UK brand name for tirzepatide, a once-weekly injection licensed for type 2 diabetes and chronic weight management. It's a dual agonist, meaning it mimics two gut hormones at once: GLP-1 and GIP. Most people know it for appetite suppression and weight loss, but its cardiovascular effects are a big part of why clinicians are comfortable prescribing it to people who aren't otherwise healthy.
The blood pressure effect isn't incidental. It shows up consistently across the tirzepatide trials, and the size of the effect is meaningful. In SURMOUNT-1 — the main trial in adults with obesity — participants on tirzepatide saw systolic blood pressure fall by around 7 to 10 mmHg and diastolic by around 4 to 5 mmHg at 72 weeks, depending on dose. For context, a 10 mmHg drop in systolic blood pressure is broadly what a single antihypertensive tablet would be expected to deliver.
In SURPASS-1 through SURPASS-5 (the type 2 diabetes trials), the picture was similar: tirzepatide lowered BP beyond what you'd expect from glycaemic improvement alone, and the effect was dose-dependent.
What's interesting is how much of this is "just" weight loss. A 2023 analysis in Cardiovascular Diabetology by Lingvay and colleagues estimated that between a third and a half of the blood pressure reduction with tirzepatide is independent of weight change. That points to direct effects of GLP-1 and GIP receptor activation — possibly through improved insulin sensitivity, reduced sodium retention, or direct vascular effects — rather than the scale alone.
So, can Mounjaro raise blood pressure?
Not meaningfully, for most people. The trial data consistently shows a net reduction, not a rise. If your numbers go up after starting Mounjaro, it's worth looking at other factors: salt intake, alcohol, stress, poor sleep, or — if it happens in the first week or two — the physical stress of nausea and dehydration from early side effects. These usually settle as your body adjusts. Persistent rises should be discussed with your prescriber.
Can you take Mounjaro if you already have high blood pressure?
In most cases, yes. The MHRA's UK product information for Mounjaro doesn't list controlled hypertension as a contraindication, and UK specialist weight management services routinely prescribe it to patients on antihypertensive medication.
In fact, the combination of obesity and high blood pressure is one of the more common presentations we see. Losing 10–20% of body weight has a large and well-established blood pressure benefit in its own right, and Mounjaro delivers weight loss in that range for most people who stay on it.
That said, "controlled" is the key word. If your blood pressure is well above target — for example, consistently above 160/100 mmHg at home — or if it's unstable and changing week to week, the sensible next step is to get it into a better range before starting Mounjaro, rather than stacking a new medication on top of an unmanaged condition. This isn't because Mounjaro is risky in that setting; it's because you'll struggle to tell what's causing what if something changes.
Combining Mounjaro with blood pressure medications
There are no direct pharmacokinetic interactions between Mounjaro and the main classes of blood pressure drugs. You can take it with:
- ACE inhibitors (ramipril, lisinopril, enalapril)
- Angiotensin receptor blockers (losartan, candesartan, valsartan)
- Calcium channel blockers (amlodipine, nifedipine, felodipine)
- Beta-blockers (bisoprolol, atenolol, carvedilol)
- Thiazide or thiazide-like diuretics (bendroflumethiazide, indapamide)
- Potassium-sparing diuretics (spironolactone)
The practical issue isn't the drug interaction — it's the additive blood pressure effect. If you're already well-controlled on, say, ramipril and amlodipine, and you add Mounjaro and lose 12 kg over six months, your blood pressure may drift lower than your target. That's usually a good problem to have, but it can mean you need to step down a dose — or drop a medication altogether.
We've had patients reduce or stop one of their antihypertensives entirely after six to twelve months on Mounjaro. Diuretics are often the first to come off, followed by calcium channel blockers. ACE inhibitors are usually kept the longest, because they have benefits beyond blood pressure (particularly in people with diabetes or known cardiovascular disease).
Never stop a blood pressure medication on your own. The right way to do this is with home monitoring data, shared with your GP or specialist, so the change is planned and not reactive.
What about diuretics specifically?
Diuretics — especially loop diuretics like furosemide — deserve a special mention. Mounjaro commonly causes nausea, vomiting and reduced fluid intake, particularly in the first few weeks and at each dose step up. If you're already on a diuretic, you're more prone to dehydration during these periods. Dehydration can trigger dizziness, low blood pressure, electrolyte imbalance and — rarely — acute kidney injury.
The fix is not to stop your diuretic. It's to make sure you're staying hydrated (small, frequent sips if nausea is bad), recognise early warning signs (dark urine, dizziness, cramping), and contact your prescriber if you can't keep fluids down for more than 24 hours.
Side effects: when blood pressure drops too low
Low blood pressure is a less common side effect of Mounjaro than high blood pressure is a starting condition, but it does happen. In the SURMOUNT and SURPASS trials, around 6.8% of tirzepatide participants experienced a blood pressure-related adverse event. Dizziness was the most common (around 4.6%), followed by hypotension (1%) and fainting, or syncope (0.5%).
To put that in perspective: if you take Mounjaro for a year, you've got a roughly 1 in 15 chance of experiencing something you'd attribute to BP — most often mild light-headedness on standing, especially early on or after a dose increase.
Signs worth knowing:
- Dizziness or light-headedness, especially when standing up from sitting or lying down
- Brief visual greying or tunnel vision on standing
- Unusual fatigue
- Headaches that feel different to your usual
- Fainting (this is rare but needs urgent review)
If you're on BP medication and you start experiencing these symptoms regularly after starting Mounjaro, it's often a sign that your BP tablets are now doing more work than they need to. A home BP reading at the time of symptoms is gold for your prescriber.
How quickly does Mounjaro lower blood pressure?
Faster than you might expect. Some of the BP effect appears within the first 4–8 weeks, before significant weight loss has happened. The larger, more durable reduction tracks with weight loss, so most of it shows up between months 3 and 9.
In SURMOUNT-1, among participants who had elevated BP at baseline (above 130/80 mmHg), the proportion with normal BP rose from 30.2% at the start to around 58% by week 72. Roughly a doubling, sustained.
If you're monitoring at home, a reasonable expectation is:
- Weeks 1–4: Small drop (2–4 mmHg systolic); mostly unchanged readings are normal.
- Weeks 5–12: More noticeable drop (5–7 mmHg systolic).
- Months 4–12: Full effect (7–10+ mmHg systolic), tracking with weight loss.
If your readings haven't moved at all by month 3 despite meaningful weight loss, flag it — it's worth checking technique (see below), underlying causes, and medication adherence.
Monitoring: the practical bit
The single most useful thing you can do when starting Mounjaro with a history of high blood pressure is to measure your BP consistently at home. Clinic readings aren't enough — they're too infrequent, and white-coat effect distorts them.
A sensible schedule:
- Baseline: A week of morning-and-evening readings before you start.
- Each dose step-up: Daily readings for the first week after each new dose.
- Ongoing: Two to three readings a week for the first three months, then weekly once things are stable.
Technique matters more than people realise. Sit quietly for five minutes first. Feet flat on the floor. Arm supported at heart level. No caffeine or exercise in the preceding half hour. Take two readings a minute apart and record the second one — the first reading is almost always artificially high.
If your cuff is registering consistently different from your GP's readings, ask to compare side-by-side at your next appointment. Most home monitors are accurate, but cuff size and fit make a big difference.
For more on the broader side effect profile, see our full Mounjaro side effects guide.
Who should be cautious or avoid Mounjaro with high BP
The MHRA's 2025 Drug Safety Update and the UK prescribing information flag a few groups where extra care is needed:
- People with severe or uncontrolled hypertension. Get your BP into a safer range first.
- People with a recent cardiovascular event. Heart attack, stroke or TIA in the last 6 months is a reason to delay starting and speak to a specialist.
- People with symptomatic orthostatic hypotension. If you already feel dizzy on standing, Mounjaro can make this worse.
- People with heart failure symptoms at rest. Not an absolute contraindication, but needs specialist input.
- People on multiple antihypertensive medications not at target. The underlying BP control needs optimising first.
For everyone else — the majority of patients with well-controlled hypertension — Mounjaro is generally considered safe and often beneficial.
Lifestyle factors still matter
Mounjaro doesn't replace the basics. The NHS blood pressure targets haven't changed, and the lifestyle pillars still pull their weight alongside medication:
- Reducing salt intake (aim for under 6 g/day; most of us eat closer to 8 g)
- Keeping alcohol within 14 units/week, spread across the week
- Regular aerobic activity — 150 minutes of moderate intensity a week
- Sleep (short sleep is a well-established BP raiser)
- Managing stress with something that actually works for you, not what looks good on Instagram
If anything, the weight loss from Mounjaro gives lifestyle changes more traction. A walk that felt impossible at 110 kg is doable at 90 kg.
This article is for general information and isn't a substitute for advice from your GP, pharmacist or prescriber. Mounjaro (tirzepatide) is a prescription-only medicine. If you're starting, changing or stopping treatment, do so under clinical supervision. Medically reviewed by Ashis Tandukar, Superintendent Pharmacist (GPhC).